Growth Opportunities

Disruptive Shifts Driving Growth in the US and EU-5 Custom Procedure Tray Sector

Escalating healthcare costs and longer patient waitlists have put pressure on healthcare facilities to reduce operational expenses and increase efficiency. Examine the growth opportunities in this landscape, unmet needs, game-changing strategies, top participants, etc.

Read more Request Info
Growth Opportunity Outlook of the Indian Healthcare Space

Examine the key transformations and business implications that executives and top players in the pharma, biotech, payer and provider industries need to consider to remain ahead of the curve in 2020. Also, explore the factors driving change and the future of this competitive sector.

Read more Request Info
COVID-19—Implications for the Healthcare Industry

The COVID-19 pandemic has brought to the fore several gaps in our understanding of health, wellness, and prevention. This analysis highlights the major opportunities for expansion, new technologies and regulations, emerging industry shifts, and much more.

Read more Request Info

CxO Insights

Building a Strategically Agile Supply Chain Engine Now to Capture Growth Opportunities in the Future

Dorman Followwill

Senior Partner

Supply Chain management and Cybersecurity are usually seen by CxOs and the Board as necessary evils, soiled signposts along the road to growth. Both are highly operational, and the heroes doing these jobs are usually only recognized when something goes wrong. But can strategic Supply Chain management be a competitive advantage, a true growth accelerator, in the post COVID world?

We believe it can, especially in our new world of pandemics and major supply chain interruptions. In this article, I want to describe two case studies of strategic Supply Chain management we were asked to undertake during the two most recent pandemics: H1N1 and COVID. The panicked origins and the strategic potential arising from these engagements have spurred us to a new appreciation for innovative and highly agile Supply Chain management in a world of increasing asymmetry.

In late Q3 2009, I received a panicked call from the Head of Procurement of Novartis’ Vaccines division (since sold to GSK) in Italy. He asked if we could conduct an emergency analysis of the global Supply Chain for chicken eggs. Why chicken eggs? Because chicken eggs are a main component of non-recombinant flu vaccines, and with the WHO officially identifying the H1N1 flu as a pandemic, the vaccine manufacturers realized their capacity for supplying an infected global patient base today would come down to how many chicken eggs they could procure yesterday. We turned out a proposal in 24 hours, and won the engagement. Focusing on demand-side and supply-side primary research, we conducted over 100 interviews across the globe, delivering a highly tuned model for scenario analysis that provided short-term and long-term, data-driven Supply Chain management for the production of the flu vaccines available at that time. The client was happy, the pandemic quickly subsided, and we all moved on to the next thing.

Schedule a consultation with an industry expert at no charge by contacting us at myfrost@frost.com. We are taking unprecedented action to make our team available to help you cut through the media and politics to get factual one-to-one guidance for the issues and opportunities that matter most to your business.

Frost Radars & Top Growth Insights

US Data Interoperability

Frost Radar - United States Healthcare Data Interoperability Market, 2020

Read more Request Info
Drug Discovery

Frost Radar - AI for Drug Discovery in the Pharmaceutical Industry, 2020

Read more Request Info
Adhesion Prevention

Growth Avenues for the Adhesion Prevention Products Sector in US and EU5

Read more Request Info

Growth Opportunities from the Evolution of EHR in Europe

Read more Request Info

Key Focus Areas and Top Growth Opportunities in the EU4 Telehealth Consultation Industry

Read more Request Info
Diagnostic Imaging

Evolving Opportunities in the Malaysian Select Diagnostic Imaging Equipment Landscape

Read more Request Info
Healthcare Industry

Growth Opportunities in the Gulf Cooperation Council Countries' Healthcare Industry

Read more Request Info
IVD Industry

Contract Manufacturing and Outsourcing in the IVD Industry Promises High-growth Potential

Read more Request Info

Upcoming Research

The Frost Radar analyzes emerging business models in the medical device landscape of atrial fibrillation (AFib) and profiles key players in this space delivering innovative solutions and maintaining leadership across segments like screening and monitoring, image-guided navigation and cardiac mapping for diagnosis and treatment, and cardiac ablation.
Request Info

What is the current and future adoption rate for oncology information systems across various regions? How is the sector developing for OIS in terms of revenues, growth rates and segment shares? What are the growth opportunities for oncology informatics software providers?
Request Info

Press Releases

Global Healthcare Interoperability Market to Witness Nearly Two-fold Growth by 2024

Frost & Sullivan’s recent analysis, Global Healthcare Interoperability Sector, Forecast to 2024, contends that interoperability has become a critical consideration for all health IT (HIT) applications. Countries where HIT interoperability standards are equally important and regulated are projected to drive the market, registering near-double-digit growth. The buoyant market for global healthcare interoperability is expected to grow at a compound annual growth rate (CAGR) of 13.8%, reaching $7.96 billion by 2024 from $4.17 billion in 2019.

Read more

Frost & Sullivan Reveals Top Five Predictions for the Global Healthcare Industry Post-COVID-19

Frost & Sullivan’s recent analysis, Post-Pandemic Global Healthcare Market Outlook, 2020, forecasts that 2020 will be an unforgiving but transformational year for the healthcare industry. As the world grapples with a global emergency caused by the COVID-19 pandemic, the healthcare industry is expected to witness a drop in growth from 5.3% to 0.6% in 2020, with revenues remaining below the $2 trillion mark.

Read more

Top Three Predictions for the Biosimilar Industry in the MENA Region Post-COVID-19

The 2020 biosimilars sector estimate for the MENA region was USD 1.6 billion with a double-digit growth rate before the pandemic hit the world. However, as the gravity of the situation started unfolding, it became explicit that there would be a decline of about 6% to 10% from the original estimate. This decline is attributed to the international supply chain disruptions, nation-wide lockdowns, overwhelmed healthcare infrastructure, poor patient adherence for injectable products and delay in the approvals and commercialization of new biosimilars in the region.

Read more

What's New?

Growth Opportunity Briefings
  • Follow us  

Subscribe to the Transformational Health Newsletter


Upcoming Events You Won't Want to Miss

Frost & Sullivan Institute

Click here to read more

Advertisement Queries

Click Here For More Info